Generic Sofosbuvir Pills for Sale in India to Treat Hepatitis C

The Drug Controller General of India approved the manufacture and sale of the generic versions of the tablet in 91 developing countries.

Dr. Reddy’s Laboratories Ltd (DRL), the country’s second largest drug maker, has tied up with Hetero Drugs to sell the generic Sofosbuvir tablets (400mg) in India. The drug will make a significant difference in the diagnosis and treatment of HepatitisC.

“The launch of Resof is in line with Dr Reddy’s philosophy of offering ‘innovative medicine at an affordable price’ and will provide significant relief to patients, resulting in potential cure and a high barrier to resistance at an affordable price for those living with Hepatitis C,” said G.V. Prasad, Co-chairman, DRL.

New Drug, Sofosbuvir, Found Very Efficient in Treating Chronic Hepatitis C Virus Infection
A new drug, Sofosbuvir, has been found very efficient in treating different types of chronic Hepatitis C Virus infection; it is in the third phase of clinical trials.

The Drug Controller General of India approved the drug for manufacture and marketing. “Clinical studies have indicated that Sofosbuvir 400 mg, in combination with other agents, achieved very high cure rates, while shortening the duration of the treatment to as little as 12 weeks and reducing or completely eliminating the need for interferon injections, depending on the viral genotype,” said DRL.

DRL has a non-exclusive licence agreement with Gilead Sciences to manufacture and sell generic versions of its chronic Hepatitis C medicines in 91 developing countries.

Source-Medindia

Hepatitis C - Causes, Symptoms, Diagnosis, Treatment, Complications, Prevention
Hepatitis C is a contagious viral disease affecting the liver that is caused by the hepatitis C virus.

Neonatal Hepatitis - Causes - Symptoms - Complications - Diagnosis - Treatment
Neonatal hepatitis is an inflammation of the liver that usually occurs in early infancy and is typically transmitted to the baby by the infected mother.

Hepatitis C Drug to be Offered Soon in India at Only One Percent of Its Cost in USA
Gilead, announced voluntary licences with seven generic drug manufacturers in India to sell lower-cost versions of a $1,000-a-pill for hepatitis C treatment in poorer countries.